Differences in the tumor biology of ovarian carcinomas probably influence operability and response to chemotherapy which are the most relevant prognostic factors. The phenotype of different malignant epithelial tumors including ovarian carcinomas is obviously associated with an activation of the EGF/TGFa signal pathway. When we analysed the expression of EGF-R and TGFa with biochemical, molecular-chemical and immunohistochemical methods in 29 different ovarian carcinomas, we found a correlation between the mRNA and protein levels of EGF-R as well as TGFa for tumors with low or high expressing rates. However, the concentration of measurable free EGF-Rs seems to depend on the amount of TGFa expression by the tumors. The EGF-R binding ligand TGFa is produced by the tumor cells; stromal cells are TGFa negative as shown by immunohistochemistry. By the use of an immunostaining index the TGFa protein concentration was measured semiquantitatively, classifying tumors according to their TGFa production rate. The comparison of TGFa mRNA amounts and staining index supports the hypothesis that TGFa is modified posttranslationally. EGF-R or TGFa expressing ovarian carcinomas had a high response rate to chemotherapy, whereas the EGF-R or TGFa negative tumors mostly exhibit a no change or progressive disease behaviour. These findings are the basis for our assumption that ovarian carcinomas with the basis for our assumption that ovarian carcinomas with an activated EGF-TGFa system are tumor biologically different compared to the EGF-R/TGFa negative tumors.

Antineoplastic Combined Chemotherapy Protocols↗

PubMedDate not supplied

Evaluation of cytokine levels in whole cell cultures of patients with gynaecological tumors as diagnostic parameters.

The measurement of the cytokine production of activated lymphocytes and monocytes supposedly provides a tool for evaluating the actual status of the cellular immunity potential of a person. We measured the levels of IFN-gamma and IL-1-alpha in the 4 day post-induction supernatants of mitogen-stimulated unseparated blood cell cultures by a rapid and sensitive immunoassay using various monoclonal and polyclonal antibodies. With this reproducible and easy-to-handle system we tested 90 patients with primary gynaecological tumors and the same number of age-matched female controls. In the blood cell cultures of the tumor patients significantly lower values of IFN-gamma and IL-1-alpha were observed, although lymphocyte and monocyte counts were almost normal. There was also a difference in the IFN-gamma-levels between the four tumors, in as much as patients with ovarian and endometrial carcinomas had significantly lower values than patients with breast and cervical carcinomas.

Adolescent↗

PubMedDate not supplied

Human papillomavirus DNA in tumor-free regional lymph nodes: a potential prognostic marker in cervical carcinoma.

PURPOSE: The medical management of women with cervical carcinoma would benefit from a test that might predict which patients have a high risk of progression or recurrence. The detection of micrometastases in regional lymph nodes may be such a test. At least 90% of cervical carcinomas worldwide contain human papillomavirus (HPV) DNA. In a pilot study, we evaluated a polymerase chain reaction-based method for the detection of human papillomavirus DNA in archival routine sections of regional lymph nodes as a marker of micrometastasis in patients with a long-term follow-up period. PATIENTS AND METHODS: We analyzed 134 archival routine slides of histologically tumor-free lymph nodes derived from 21 patients with clinically and pathologically determined stage Ib, IIa, and IIb HPV-16 positive cervical carcinoma. The patients had been selected for good (still alive with a follow-up time of at least 5 years) or fatal outcome (dead of disease within 3 years). The amount of HPV-16 DNA was estimated by comparison with standards. RESULTS: All patients without strongly HPV-positive lymph nodes survived. In contrast, 8 of 12 women with strongly HPV-positive lymph nodes died of cervical carcinoma. CONCLUSIONS: In patients with cervical cancer, an approach based on a PCR test for HPV DNA in tumor-free regional lymph nodes may allow early identification of women at high risk for relapse who should receive adjuvant treatment.

Adult↗